Swedbank AB Sells 16,356 Shares of Moderna, Inc. $MRNA

Key Points

• Swedbank AB has reduced its stake in Moderna, Inc. by 82.6%, selling 16,356 shares and now holding only 3,446 shares valued at approximately $95,000.
• Institutional investors hold a significant 75.33% of Moderna's stock, indicating a strong institutional interest in the company despite recent fluctuations.
• After reporting earnings of ($2.13) EPS for the last quarter, Moderna's revenue was down 41.1% year-over-year, despite exceeding analysts' expectations with $142 million in revenue.

Swedbank AB lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 82.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,446 shares of the company's stock after selling 16,356 shares during the quarter. Swedbank AB's holdings in Moderna were worth $95,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd acquired a new position in Moderna in the 1st quarter valued at approximately $25,000. SVB Wealth LLC acquired a new position in shares of Moderna in the 1st quarter worth approximately $28,000. Costello Asset Management INC bought a new stake in Moderna during the 1st quarter worth approximately $30,000. Sentry Investment Management LLC bought a new stake in Moderna during the 1st quarter worth approximately $31,000. Finally, Deseret Mutual Benefit Administrators grew its position in Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after acquiring an additional 392 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on MRNA shares. Cowen initiated coverage on Moderna in a research report on Sunday, July 13th. They issued a "hold" rating on the stock. Citigroup started coverage on Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 price objective on the stock. Leerink Partners dropped their price objective on Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research note on Friday, August 22nd. Morgan Stanley reissued an "equal weight" rating and issued a $32.00 price target on shares of Moderna in a research note on Friday, August 1st. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $41.81.

Moderna Price Performance

Shares of MRNA opened at $26.56 on Tuesday. Moderna, Inc. has a one year low of $23.15 and a one year high of $67.96. The company has a market cap of $10.33 billion, a P/E ratio of -3.53 and a beta of 1.93. The firm has a 50 day simple moving average of $27.44 and a two-hundred day simple moving average of $27.83.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.